0.29
0.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Microbix Biosystems
Its shares trade on Toronto Stock Exchange under the ticker MBX.TO. It has been listed since 1 October 1992. In the fiscal year to 30 September 2025, it reported revenue of C$18.6m and a net loss of C$2.2m. At that date it held total assets of C$37.4m and shareholders' equity of C$27.8m.
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm has developed and acquired two technologies: Kinlytic Urokinase and LumiSort. Kinlytic Urokinase is a biologic thrombolytic drug used to treat blood clots. LumiSort is a technology for ultra-rapid and efficient sorting of somatic cells that can be used to enrich cell populations of interest. The firm's catalogue of antigens covers over 30 bacterial and viral pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually-transmitted and insect-borne diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Oct 1992
- Employees
- 20
- Website
- microbix.com ↗
Leadership
Pay as last reported
- Mr. Martin MarinoIndependent Chairman of the Board
- Mr. Cameron GroomePresident, Chief Executive Officer and Director, since 2012C$660,142
- Dr. Peter BlecherIndependent Director
- Dr. Mark CochranIndependent Director$165,000
- Mr. Vaughn Embro-pantalonyIndependent Director, since 2007C$221,516
- Mr. Joseph RennerIndependent Director
- Ms. Jennifer StewartIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Microbix Biosystems Inc boasts a strong portfolio of proprietary technologies and intellectual property, including its viral antigen production capabilities.
- The company has established itself as a leader in the development and manufacture of critical biological products used in diagnostics, quality control, and research.
- Microbix has a diverse range of end markets and customers, reducing dependency on any single sector or client.
Weaknesses
- The company heavily relies on key customers for a significant portion of its revenue, which may present business continuity risks in case of customer departure.
- Microbix faces competition from both established players and emerging companies in the biotherapeutics and diagnostics markets.
- Limited financial resources may hamper the company's ability to invest in research and development and expand its operations.
Opportunities
- The increasing demand for biopharmaceutical products and diagnostic solutions presents significant growth opportunities for Microbix Biosystems Inc.
- Expanding into new geographic markets and strategic partnerships with leading industry players can help the company to strengthen its market position.
- Leveraging its expertise in viral antigen production, Microbix can explore opportunities in vaccine development, particularly amid the current global health concerns.
Threats
- Rapidly changing market dynamics and regulatory requirements could impact the company's ability to adapt and stay competitive.
- Economic downturns or global crises may lead to reduced demand for the company's products and services.
- The entry of new competitors with disruptive technologies and lower cost structures poses a threat to Microbix's market share and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.